Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology has applied to the ASX for quotation of 270,471 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The additional shares modestly expand the company’s free float and capital base, potentially improving liquidity in RAC stock while reflecting ongoing participation by holders of its equity-linked instruments.
The most recent analyst rating on (AU:RAC) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australia-listed biotechnology company operating in the oncology sector, focused on developing cancer-related therapies and associated technologies. Its shares trade on the ASX under the ticker RAC, providing investors exposure to early-stage and emerging cancer treatment opportunities.
Average Trading Volume: 184,050
Technical Sentiment Signal: Buy
Current Market Cap: A$458.6M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.